Prathima Prodduturi, M.D.
- Associate Physician Diplomate
Philosophy of Care
Our mission is to provide comprehensive and compassionate care to our patients and their care givers. An affiliation with UC Davis, our patients receive access to many clinical trials and leading edge research. We make sure every patient receives the very best treatment possible by practicing the art and science of medicine.
Dr. Prodduturi is a general hematologist/oncologist offering care for patients with various blood disorders and cancers. She has special interests and experience in treating patients with breast cancer and lymphomas.
Hematology and Oncology
M.B.B.S., Osmania Medical College, Hyderabad, N T R University of Health Sciences, India 2003
Internship: Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago IL 2006-2007
Internal Medicine, University of North Dakota, Fargo ND 2007-2009
Hematology/Oncology, University of Nebraska Medical Center, Omaha NE 2009-2012
American Board of Internal Medicine,
American Board of Internal Medicine, Hematology and Oncology,
CA Medical Board, License, 2018
Educational Commission For Foreign Medical Graduates (ECFMG),
American Society of Clinical Oncology
American Society of Hematology
Canadian Medical Association
Honors and Awards
Clinical Skills and Scholarship Award (Best Intern) at John H Stroger Jr. Hospital of Cook County, Chicago, 2007
Graduated top of the class in medical school, 2013
Select Recent Publications
Prodduturi P, Bierman JP. New and emerging treatments in Primary Central Nervous System Lymohoma. Clinical Medicine Insights: Oncology. 2012 May.
Prodduturi P, Perry A, Aoun P, Akhtari M. "Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: a case report and review of the literature. Journal of Oncology Pharmacy Practice. 2012 March.
Prodduturi P, Armitage JO. Reduced Intensity Treatment in Early Stage Hodgkin Lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2011 November.
Nathan S, Amin A, Prodduturi P. Older Age Strongly Impacts Selection for Early Invasive Therapies in Cardiogenic Shock with Differential Patterns of 1-Year Survival Observed in Younger vs. Older Patients. Circulation. 2006 May;113(e788-e834):179.